Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression.
van Houdt IS, Sluijter BJ, Moesbergen LM, Vos WM, de Gruijl TD, Molenkamp BG, van den Eertwegh AJ, Hooijberg E, van Leeuwen PA, Meijer CJ, Oudejans JJ. van Houdt IS, et al. Among authors: molenkamp bg. Int J Cancer. 2008 Aug 1;123(3):609-15. doi: 10.1002/ijc.23543. Int J Cancer. 2008. PMID: 18498132 Free article.
Local administration of granulocyte/macrophage colony-stimulating factor increases the number and activation state of dendritic cells in the sentinel lymph node of early-stage melanoma.
Vuylsteke RJ, Molenkamp BG, Gietema HA, van Leeuwen PA, Wijnands PG, Vos W, van Diest PJ, Scheper RJ, Meijer S, de Gruijl TD. Vuylsteke RJ, et al. Among authors: molenkamp bg. Cancer Res. 2004 Nov 15;64(22):8456-60. doi: 10.1158/0008-5472.CAN-03-3251. Cancer Res. 2004. PMID: 15548718 Clinical Trial.
Melanoma Sequentially Suppresses Different DC Subsets in the Sentinel Lymph Node, Affecting Disease Spread and Recurrence.
van den Hout MFCM, Koster BD, Sluijter BJR, Molenkamp BG, van de Ven R, van den Eertwegh AJM, Scheper RJ, van Leeuwen PAM, van den Tol MP, de Gruijl TD. van den Hout MFCM, et al. Among authors: molenkamp bg. Cancer Immunol Res. 2017 Nov;5(11):969-977. doi: 10.1158/2326-6066.CIR-17-0110. Epub 2017 Sep 21. Cancer Immunol Res. 2017. PMID: 28935649
Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I-II Melanoma: Data from Two Randomized Phase II Trials.
Koster BD, van den Hout MFCM, Sluijter BJR, Molenkamp BG, Vuylsteke RJCLM, Baars A, van Leeuwen PAM, Scheper RJ, Petrousjka van den Tol M, van den Eertwegh AJM, de Gruijl TD. Koster BD, et al. Among authors: molenkamp bg. Clin Cancer Res. 2017 Oct 1;23(19):5679-5686. doi: 10.1158/1078-0432.CCR-17-0944. Clin Cancer Res. 2017. PMID: 28972083 Clinical Trial.
T cell infiltration on local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A+CD141+ cDC1 and CD14+ antigen-presenting cell recruitment.
Koster BD, López González M, van den Hout MF, Turksma AW, Sluijter BJ, Molenkamp BG, van Leeuwen PA, Vosslamber S, Scheper RJ, van den Eertwegh AJ, van den Tol MP, Jordanova EJ, de Gruijl TD. Koster BD, et al. Among authors: molenkamp bg. J Immunother Cancer. 2021 Mar;9(3):e001962. doi: 10.1136/jitc-2020-001962. J Immunother Cancer. 2021. PMID: 33737341 Free PMC article.
Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load.
Molling JW, Kölgen W, van der Vliet HJ, Boomsma MF, Kruizenga H, Smorenburg CH, Molenkamp BG, Langendijk JA, Leemans CR, von Blomberg BM, Scheper RJ, van den Eertwegh AJ. Molling JW, et al. Among authors: molenkamp bg. Int J Cancer. 2005 Aug 10;116(1):87-93. doi: 10.1002/ijc.20998. Int J Cancer. 2005. PMID: 15756674 Free article.
21 results